Navigation Links
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Date:9/5/2008

ary treatment for most subtypes of PTCL remains anthracycline-based regimens, predominantly the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). With the exception of ALK-positive ALCL, PTCL subtypes respond poorly to these regimens. The use of radiotherapy, with or without chemotherapy, is preferred as front line treatment of extranodal NK/T-cell lymphoma. The majority of patients with PTCL will relapse after primary therapy. A number of chemotherapy regimens are used for salvage therapy. However, there is currently no consensus regarding the optimal treatment approach for PTCL salvage therapy.

About Belinostat

Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid tumors and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade(R) (bortezomib) for injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents. Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for cutaneous and peripheral T-cell lymphomas, B-cell lymphomas, AML, mesothelioma, soft tissue sarcoma, MDS, and liver, colorectal, and ovarian cancers, either alone or in combination with anti- cancer therapies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. Several trials in the belinostat program are conducted under a Clinical Trail Agreement (CTA) under which the NCI sponsors clinical tri
'/>"/>

SOURCE TopoTarget
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
2. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
3. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
4. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
5. Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
8. Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
9. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
10. QLT announces positive Health Canada decision on Aczone(R)
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... CORAL SPRINGS, Florida , September 19, 2014 /PRNewswire/ ... biotech companies release latest developments, patents and results of ... (OTC: GNSZ), Eli Lilly and Company (NYSE: ... ), Celgene Corporation (NASDAQ: CELG ) and ... (OTCQB: GNSZ), a leader in developing prodrug therapeutics for ...
(Date:9/19/2014)... , September 19, 2014 ... 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... science and medical research in the field of growth  ... KGaA, Darmstadt, Germany , today announced ... (GGI) for 2014. The awards were announced during a ...
(Date:9/18/2014)... About POCT POCT, ... clinical laboratory. It helps in making fast clinical ... medication. POCT is gaining popularity due to the ... as diabetes, heart disease, and obesity. It is ... to minimize errors during the diagnosis of patients. ...
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... Squibb,Company (NYSE: BMY ) today announced that the ... of the Board. Mr. Cornelius, who,was named chief executive ... as well. Mr. Cornelius, current employment contract, which,expires in ... Lewis B.,Campbell, chairman, president and CEO, Textron Inc., as ...
... Feb. 12 NanoLogix, Inc. (OTC:,NNLX) a ... is currently featuring broadcast articles on the ... near Erie, Pennsylvania.,The articles, produced by Lisa ... Environment Report", began airing on various affiliated ...
... 12 The Board of,Directors of Baxter International Inc. ... $0.2175 per share of Baxter common stock., This ... was,increased earlier this year by 30 percent. This quarterly ... record as of March 10, 2008., Baxter International ...
Cached Biology Technology:Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board 2National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welch's Foods 2
(Date:9/18/2014)... in the eastern Mediterranean Sea pose a major threat ... to expand as the climate warms, a new study ... led by Dr Adriana Vergs of UNSW Australia and ... Studies in Spain, is published in the Journal ... than 1000 kilometres of coastline in Turkey and Greece, ...
(Date:9/18/2014)... world-leading provider of scientific, technical and medical information ... Society (ARMS), recognized the academic research achievements of ... Researcher of the Year Awards. , The award ... Centre and in conjunction with the ARMS 2014 ... and New Zealand,s scientific community. Guest of honour ...
(Date:9/18/2014)... Sticklebacks, the roaches of the fish world, are the ... control body shape. They,ve moved from the ocean into ... the world, each time changing their skeleton to adapt ... and freshwater populations of sticklebacks now have turned up ... evidence that a simple change in that gene,s regulation ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3
... , KANSAS CITY, MOTwo opposing teams battle it out ... One, the activators, keeps DNA open to enzymes that ... effort by twisting DNA into an inaccessible coil around ... to DNA by enzymes that elongate an RNA strand. ...
... MA A team of scientists, including faculty at the ... that influences survival time in amyotrophic lateral sclerosis (ALS, also ... Nature Medicine , describes how the loss of activity ... people with the disease. When coupled with a UMMS study ...
... disease and infection might be used as weapons is truly ... weapons have been around since ancient times. * ... medicines have made the world a safer place against a ... remains all too easy today to uncork a nasty cloud ...
Cached Biology News:Controlling gene expression: How chromatin remodelers block a histone pass 2Controlling gene expression: How chromatin remodelers block a histone pass 3Scientists identify new gene that influences survival in ALS 2Boston subway system to be used to test new sensors for biological agents 2
...
...
... Streptavidin Sepharose High Performance, 5 ml. ... used in HiTrap Streptavidin columns for ... for packing into Tricorn 5/50 GL, ... larger scale purifications are required.Extremely useful ...
Luminometers...
Biology Products: